Product name: Soysaponin II
Synonym name:
Catalogue No.: BP4255
Cas No.: 55319-36-3
Formula: C₄₇H₇₆O₁₇
Mol Weight: 913.108
Botanical Source: Glycine max
Type of Compound: Triterpenoids

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle

Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.

The product could be supplied from milligrams to grams
Inquire for bulk scale.

For Reference Standard and R&D, Not for Human Use Directly.

Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Soysaponin II, a triterpene saponin derived from soybeans, has attracted widespread attention in the field of natural drug research in recent years. Saponin compounds demonstrate unique advantages in various pharmacological effects such as anti-inflammatory, anti-tumor, and antiviral properties due to their structural diversity and rich bioactivity. Soy saponin II not only possesses the typical triterpene saponin structural features but also demonstrates potential pharmacological activity in the prevention and treatment of viral infection-related diseases, particularly showing good effects in regulating immune responses and inhibiting viral replication. This paper will systematically review the chemical structure and physicochemical properties, plant origin, and extraction methods of soy saponin II, delve into its pharmacological activity and mechanism of action, evaluate its druggability and pharmacokinetic characteristics, and look ahead to its clinical application prospects.

Chemical structure and physicochemical properties

Soy saponin II has a chemical structure belonging to the triterpene saponin class, with a molecular formula of C_45H_72O_17 and a molecular weight of 913.1080. Its core backbone is a pentacyclic triterpene structure, connecting multiple glycosyl residues to form a typical saponin structure. The compound has a LogP value of 2.4298, showing moderate lipid solubility that facilitates penetration of biofilms in vivo. Its topological pole surface area (TPSA) is 274.75 Ų, indicating high molecular polarity, which may affect oral absorption and membrane permeability. Water solubility is 0.1959, classifying it as a low-solubility compound, suggesting that solubility enhancement strategies should be considered in formulation development. The low permeability of the blood-brain barrier suggests its limited distribution in the central nervous system. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. Ames mutagenicity test results were zero, indicating a low genotoxicity risk.

Plant Origins and Extraction Methods

Soy saponin II is mainly found in soybean (Glycine max) seeds and their processing by-products. Soybeans are an important global food and oilseed crop, with rich saponin content and diverse structures. The extraction of soybean saponins typically uses organic solvent extraction binder-liquid distribution technology, with ethanol or methanol as the main extractants, supplemented by aqueous phase adjustment to improve the leaching rate of saponins. The extract was concentrated, precipitated, and separated by column chromatography, and finally purified by high-performance liquid chromatography (HPLC) to obtain soybean saponin II. In recent years, the application of ultrasound-assisted extraction and microwave-assisted extraction technologies has improved extraction efficiency and purity, reduced the use of organic solvents, and aligned with the concept of green chemistry. During purification, silica gel column chromatography, reversed-phase C18 column chromatography, and preparative HPLC are commonly used separation methods.

Pharmacological activity research

Soy saponin II exhibits significant pharmacological activity under various pathological conditions, especially in immune regulation and antiviral effects related to viral infection. In vitro and in vivo studies have shown that soy saponin II can inhibit the replication of various viruses, including influenza viruses and HIV, and has broad-spectrum antiviral potential.

Its antiviral activity mainly manifests as:

1. Inhibition of viral replicase activity: Soy saponin II inhibits reverse transcriptase (RT) and HIV-1 reverse transcriptase (HIV-1RT), blocking the replication process of the viral genome.
2. Regulation of immune-related signaling pathways: By regulating the TLR4 (Toll-like receptor 4) and NFKB1 (nuclear factor κB subunit 1) signaling pathways, it alleviates inflammatory responses triggered by viral infection and enhances the body's antiviral immunity.
3. Inhibition of inflammasome activation: The inhibitory effect on NLRP3 inflammasomes helps control excessive inflammatory responses and reduces tissue damage.
4. Regulation of interferon signaling: enhances antiviral interferon responses by affecting IFNAR1 (interferon α/β receptor 1) and IRF3 (interferon regulatory factor 3) signals.

In addition, soy saponin II also exhibits certain antioxidant and cell-protective effects, possibly promoting tissue repair by reducing oxidative stress and apoptosis.

Mechanism of action and molecular targets

The multi-target mechanism of soy saponin II is an important basis for its pharmacological activity. Its main targets include:

• TLR4: As a key receptor in the innate immune system, TLR4 recognizes virus-related molecular patterns (PAMPs), initiates downstream signaling, activates NFKB1, and induces inflammatory factor expression. Soy saponin II reduces the release of pro-inflammatory factors by inhibiting TLR4 activation, thereby alleviating inflammatory responses.
• NFKB1: As a core transcription factor for inflammatory signals, NFKB1 regulates the expression of various inflammatory genes. Soy saponin II inhibits NFKB1 activation and reduces the production of inflammatory mediators.
• NLRP3 inflammasomes: Activation of NLRP3 inflammasomes leads to the release of pro-inflammatory cytokines IL-1β and IL-18. Soy saponin II reduces inflammatory responses by inhibiting NLRP3 assembly and activation.
• Reverse transcriptase (RT) and HIV-1RT: Soy saponin II directly inhibits viral reverse transcriptase activity, blocking viral genome replication.
• Interferon signaling pathways (IFNAR1, IRF3): By enhancing interferon signaling, it promotes the expression of antiviral genes and enhances the body's antiviral ability.
• NA (neuraminidase) and HA (hemagglutinin): Although current evidence is limited, soy saponin II may hinder viral invasion and release by affecting the function of viral surface proteins NA and HA.

Additionally, RRM1 (the M1 subunit of ribonucleotide reductase reductase), as a key enzyme for nucleotide metabolism, may also be regulated by soybean saponin II, affecting the nucleotide supply required for viral replication.

In summary, soy saponin II achieves antiviral and immunomodulatory functions through multi-target and multi-pathway synergistic effects, providing a theoretical basis for its development as an antiviral drug.

Druggability evaluation and pharmacokinetics

The druggability parameters of soy saponin II indicate that it has certain development potential. Its relatively large molecular weight (913.1080 Da), which exceeds the ideal range of traditional oral drugs (<500 Da), may limit its oral bioavailability. A high TPSA value (274.75 Ų) and low water solubility (0.1959 mg/mL) also suggest limited absorption, requiring optimization of drug formulations to improve solubility and membrane permeability.

The LogP value was 2.4298, indicating moderate lipid solubility and favorable penetration of cell membranes, but combined with high polarity and large molecular weight, overall oral absorption may be poor. The low permeability of the blood-brain barrier limits its application in central nervous system diseases, but it reduces the risk of central nervous system toxicity.

The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity and good safety. The Ames test result was 0, showing no mutagenicity, meeting safety requirements.

Currently, research on pharmacokinetics is relatively limited. It is speculated that oral absorption is limited, possibly through gut microbial metabolism or enzymatic hydrolysis to produce active metabolites. Its distribution in the body may mainly concentrate in metabolic organs such as the liver and kidneys. Metabolic pathways may involve the hepatic cytochrome P450 enzyme system, but specific enzyme species and metabolites require further research. Excretion routes are presumed to be bile and feces.

To overcome druggability limitations, strategies such as nanocarriers, liposomal encapsulation, and prodrug design are worth exploring to improve bioavailability and targeting.

Prospects and outlooks for clinical applications

Soy saponin II, as a natural triterpene saponin, combines both antiviral and immunomodulatory functions, with broad clinical application potential. Its mechanism of action in viral infections, especially influenza and HIV, is well documented, demonstrating its value as an adjunctive antiviral therapy.

The key to future clinical applications lies in:

1. Formulation optimization: Enhancing oral bioavailability and targeted delivery capability to enhance efficacy.
2. Safety Evaluation: Systematic toxicology and long-term safety studies are conducted to ensure clinical application safety.
3. Clinical trial design: Conduct randomized controlled clinical trials targeting patients with viral infections to verify efficacy and safety.
4. Combination therapy strategies: Explore synergies with existing antiviral drugs to reduce resistance risks and improve treatment outcomes.
5. Indication expansion: Based on its immunomodulatory effects, study its potential applications in autoimmune diseases, chronic inflammation, and tumors.

Moreover, with the development of natural product pharmacology and molecular biology technologies, optimizing the efficacy and pharmacokinetic properties of soybean saponin II through structural modification and drug design will further drive its clinical translation.

Conclusion

Soy saponin II, as a triterpene saponin natural product with a unique structure and multi-target mechanism, shows broad research and application prospects in antiviral and immunomodulatory fields. Its multi-target ability to regulate viral replication and inflammatory responses offers new ideas for the development of antiviral drugs. Although druggability faces certain challenges, modern drug formulation technologies and structural optimization are expected to overcome limitations in bioavailability and pharmacokinetics. In the future, combined with systematic pharmacological research and clinical validation, soy saponin II is expected to become an important candidate for natural antiviral drugs, contributing new strength to the prevention and treatment of viral diseases.